

**From:** [SANTE INFO](#)  
**To:** [REDACTED]@yahoo.com"  
**Subject:** FW: New thereapeutics  
**Date:** vendredi 2 juillet 2021 16:09:00

---

Dear [REDACTED],

On 29 June the EC revealed the list of 5 promising therapeutics that are in an advanced stage of development and have potential to be among the three new COVID-19 therapeutics to receive authorisation by October (the target set in the strategy) provided that the final data demonstrate their safety, quality and efficacy. The list is based on objective criteria, namely the rolling review evaluation by the European Medicines Agency (EMA).

For more information, please check [Commission identifies five promising candidate therapeutics \(europa.eu\)](#) or the [press release](#) .

The above mentioned initial list of five therapeutics includes the most advanced COVID-19 therapeutics in terms of development. These therapeutics are already under evaluation by EMA. A rolling review is a regulatory tool that EMA uses to speed up the assessment of a promising medicinal products during a public health emergency. EMA includes products in the rolling review procedure based on promising preliminary results from clinical studies.

The Commission is also working on a framework for a broader and diverse portfolio of therapeutics with the help of the newly established expert group on variants. [The selection process will be objective and science based](#). The selection criteria will be also agreed with the Member States. Such portfolio will cover different types of products needed for different patient populations and different stages and severity of the disease.

For more information on EMA scientific work you may check the EMA page on COVID-19 therapeutics: [Treatments and vaccines for COVID-19 | European Medicines Agency \(europa.eu\)](#) or the specific page for scientific advice: [Scientific advice and protocol assistance | European Medicines Agency \(europa.eu\)](#)

Kind regards,

SANTE INFO

---

**From:** [REDACTED]@yahoo.com>

**Sent:** Wednesday, June 23, 2021 4:24 PM

**To:** [REDACTED]@ec.europa.eu>

**Subject:** New thereapeutics

Hi [REDACTED],

Hope all is well with you and your friends and family. We have all certainly suffered enough already.

So I am curious as to the progress of the new strategy proposed a few months ago by the European Commission for the rapid advancement of therapeutics for COVID.

Two questions I have in this regard that perhaps you can guide me for more information on the latest developments.

what therapeutics have been identified thus far?

Has Leronlimab by Cytodyn Corporation been adopted yet or on your candidate list for consideration?

what are the opinions on already existing therapies like HCL and Ivermectin? Are they considered also or in a separate category?

Best Regards, May we get through this together.

*"We will do so by investing in research and innovation, the identification of new promising medicines, ramping up production capacity and supporting equitable access. Our Therapeutics Strategy is a strong European Health Union in action."*

Commissioner for Innovation, Research, Culture, Education and Youth, Mariya Gabriel, said: *"By increasing vaccine availability across Europe, more and more Europeans are now protected against COVID-19. In the meantime, the development of innovative medicines to treat coronavirus patients remains a priority when it comes to saving lives. Research and innovation is the first step to finding effective and safe therapeutics, which is why we are proposing to establish a new COVID-19 'therapeutics innovation booster' and will invest € 90 million in population studies and clinical trials."*

#### Background

The Strategy on COVID-19 therapeutics complements the [EU strategy for COVID-19](#) vaccines from June 2020 and builds on ongoing work by the European Medicines Agency and the Commission to support research, development, manufacturing and deployment of therapeutics.

The Strategy forms part of a strong [European Health Union](#), using a coordinated EU approach to better protect the health of our citizens, equip the EU and its Member States to better prevent and address future pandemics, and improve the resilience of Europe's health systems."